 assess daili prepar isoniazid rifampin control trial regimen smear-posit pulmonari tuberculosi singapor tuberculosi service/british medic research council studi singapor patient sputum smear-posit pulmonari tuberculosi random daili chemotherapi streptomycin isoniazid rifampin pyrazinamid month month month streptomycin patient time weekli isoniazid rifampin total durat month initi period daili chemotherapi patient random hrz combin formul rifat tablet mg isoniazid mg rifampin mg pyrazinamid separ drug rifat versu separ drug common spontan complaint nausea vomit patient rifat separ drug other advers effect similar proport seri patient drug-suscept strain tubercl bacilli pretreat bacteriolog failur chemotherapi month subsequ follow-up bacteriolog relaps patient rifat patient drug evid therapeut benefit shrz administr month streptomycin hrz relaps rate rifat seri further follow-up result studi combin prepar